Aptevo Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company headquartered in Seattle, Washington, United States. For investors, it is best viewed as a development-stage oncology and hematology story rather than a revenue-generating commercial pharma business. The company was formed following the separation of Emergent BioSolutions’ development-focused biopharmaceutical operations, with the objective of concentrating on novel immune-oncology programs. Its strategy is built around proprietary platforms, ADAPTIR and ADAPTIR-FLEX, which are designed to create bispecific and trispecific antibody-based therapeutics that can redirect the immune system toward cancer cells. Aptevo’s core business is the discovery and development of cancer therapies, with emphasis on hematologic malignancies and selected solid tumors. The lead clinical asset is mipletamig, which the company has positioned as its main therapeutic candidate in acute myeloid leukemia (AML). Beyond the lead program, Aptevo has continued to expand its CD3-focused pipeline with preclinical and early-stage assets such as APVO455, APVO451, APVO452, and APVO442. These programs reflect management’s goal of building a differentiated family of T-cell engager molecules using a common CD3 binding domain, while exploring applications across multiple tumor types. In a competitive context, Aptevo operates in a crowded field that includes large multinational pharmaceutical groups and a broad set of oncology biotechs pursuing T-cell engagers, bispecifics, and next-generation immunotherapies. Its competitive edge depends on scientific differentiation, platform versatility, and the clinical readout potential of mipletamig. Geographically, Aptevo is primarily a United States company, with operations, corporate headquarters, and capital markets exposure centered in the U.S. The company is listed on the NASDAQ market, which underscores its profile as a small-cap, high-risk, high-volatility biotech issuer. Recent highlights include the expansion of its CD3 pipeline in 2025, when it added several new bispecific and trispecific candidates, and a 2026 company update indicating improved operational momentum and cash resources expected to support operations into the fourth quarter of 2026. For equity investors, Aptevo remains a classic catalyst-driven biotech: valuation is mainly tied to clinical progress, regulatory milestones, financing needs, and the market’s confidence in its proprietary platform.